New Delhi, Dec 24: Reforms made by the government coupled with private partnerships played a crucial role in the growth of India’s space industry in 2024, said the Indian Space Association (ISpA), noting that 2025 is poised to be a year of transformative developments.

Lt. Gen. AK Bhatt (Retd), Director General, ISpA stated that government reforms like the Foreign Direct Investment policy, the Rs 1,000 crore Venture Capitalist fund, and a thriving startup ecosystem, coupled with dynamic public-private collaborations propelled space sector growth.

“The Indian government’s continued focus on strategic policy reforms not only opens the door for significant private sector investment but also ensures that India stays at the forefront of global space innovation. With the continuous support from the government and the push for the public,” Bhatt said.

“The private space sector is witnessing a major growth in the startup ecosystem driven by favourable policy reforms like the liberal FDI policy announced this year,” he stated, adding that this will give the country “access to the latest tech advances and funds” both from Indian and global investors.

The FDI policy in the space sector was launched under the Indian Space Policy 2023 in March. It allows for 100 per cent FDI under the automatic route for satellite components and systems, up to 74 per cent for satellite manufacturing and operation, and 49 per cent for launch vehicles and spaceports.

In October, the Cabinet approved a Rs 1,000 crore VC Fund for the space sector, bolstering startups and private players.

It also approved Phase III of the Space-Based Surveillance (SBS-III) project, targeting the launch of 52 satellites to enhance surveillance. This involved the manufacturing of 31 satellites by the private sector, providing immense opportunities to the industry.

Further, the year also witnessed the laying of the foundation stone for India’s second spaceport in Kulasekharapattinam, Tamil Nadu.

Tata Advanced Systems and Satellogic launched India’s first private sub-metric high-resolution Earth Observation satellite in April.

In May, Agnikul Cosmos made history with the launch of “Agnibaan – SOrTeD,” the world’s first rocket powered by a fully 3D-printed, semi-cryogenic engine.

Funding for Indian space-tech startups reached $76.79 million in 2024, bringing total funding to $463.24 million to date. This includes Pixxel, GalaxEye, Dhruva Space, XDLink Labs, Piersight, and EtherialX.

Notably, this year, ISRO’s commercial arm, NSIL, invited private firms to apply for the end-to-end manufacturing of the Launch Vehicle Mark-III, used in Chandrayaan-2 and Chandrayaan-3.

IN-SPACe, under the Department of Space, also called for initial bids from domestic companies to design, build, and operate Earth Observation satellites. These initiatives mark the Centre’s push to become a key customer for India’s private space sector through a public-private partnership (PPP) model, transforming the space sector, Bhatt said.

New Delhi, Dec 19: India is well on its way to having the second-largest metro network in the world with 993 km of Metro rail already operational in 23 cities across the country and about 997 km under construction in 28 cities, Minister for Housing & Urban Affairs Manohar Lal Khattar has said.

The Union Minister made an elaborated presentation on Urban Transport to the consultative committee members of Parliament attached to MoHUA, according to an official statement on Thursday.

He emphasised that Urban Mobility is an important aspect to tackle the rising urban population and the government is working relentlessly to strengthen the Urban Transport Network across the country.

The participants were briefed about Metro Rail Policy 2017 and Metro Networks across the cities including Delhi, Jaipur, Patna and Lucknow.

The members were also briefed about the ongoing projects of RRTS (Regional Rapid Transport System) high speed train network, including its funding pattern.

The briefing to members also covered initiatives taken to promote indigenisation of technologies under Make in India and promote Aatmanirbhar Bharat.

The briefing also mentioned PM-eBus Sewa, a scheme for augmenting city bus operations by deploying 10,000 e-buses on the Public Private Partnership (PPP) model.

Salient features of this scheme include deployment of 10,000 e- buses on PPP model, bus operations support for 10 years, support for development and the upgradation of bus depots and support for behind-the-meter power infrastructure.

The service aims to cover cities with 3 to 40 lakh population.

The briefing also covered ‘One Nation One Card’, an indigenously developed National Common Mobility Card (NCMC), launched by Prime Minister Narendra Modi in March 2019 to enable seamless travel through Metro, Rail, Bus and other Public Transport Operators.

During the meeting, the Members of Parliament raised issues pertaining to urban mobility which included matters related to last mile connectivity, enhancement of amenities, metro connectivity in their respective states, scaling up of metro operations in the country, ease of travel and passenger comfort.

The MPs who attended the meeting include Rajiv Pratap Rudy, Dinesh Sharma, Ajay Maken, Kamaljeet Sherawat, P.N. Vasava, Prof V.E. Gaikwad, Kavita Patidar, B.M. Sutariya , V.E. Vaithilingam , G. Lakshminarayana, Ramvir Singh Bidhuri and Y. Chandolia.

The Minister asked the officials that suggestions from members received should be reviewed and information sought by them should be provided.

New Delhi, Dec 19: The first blood-stage malaria vaccine RH5.1/Matrix-M has the potential to be a component within a developing malaria vaccine strategy, said a report on Thursday.

The report by GlobalData, a data and analytics company, showed that there are 11 other malaria vaccines currently in Phase II development.

As per a recent study by researchers in Burkina Faso and the UK, RH5.1/Matrix-M is safe, effective, and highly immunogenic.

The double-blind, randomised, controlled, phase 2b trial, analysed 361 children between the ages of 5 and 17 months showed that RH5.1/Matrix-M is 55 per cent effective against clinical malaria when administered in a delayed third-dose regimen at 0, 1, and 5 months.

Further, the vaccine demonstrated over 80 per cent efficacy against high levels of malaria parasites, which indicates the vaccine would be effective at preventing severe disease. RH5.1/Matrix-M was found to be generally safe and well-tolerated, with no serious adverse events being reported, revealed the findings published in The Lancet Infectious Diseases.

“RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market. This could be a much-needed addition to the currently available malaria vaccines and provide an important second line of defense for those most at risk of contracting malaria,” said Stephanie Kurdach, Infectious Disease Analyst at GlobalData.

Malaria is a mosquito-borne disease, caused by parasitic Plasmodium protozoans, spread primarily through the bite of an infected female Anopheles mosquito. Typically, the symptoms can range from fever, chills, and headache to confusion, seizures, and difficulty breathing.

Kurdach noted that although there is progress and some nations have been certified as malaria-free, the burden of malaria remains high, particularly within the World Health Organization’s (WHO) African Region.

There are currently only two malaria vaccines, that are WHO prequalified and recommended for use in children: GSK’s Mosquirix and Serum Institute of India’s R21/Matrix-M.

These vaccines work to intercept malaria infection by targeting the early sporozoite stage of the parasite.

However, as immunity wanes with time, sporozoites can infect the liver and lead to blood-stage clinical malaria infection.

The development of a blood-stage malaria vaccine would replace these vaccines as well provide a second line of defense.

“There are 11 other malaria vaccines currently in Phase II development, including pre-erythrocytic vaccines and blood-stage vaccines from manufacturers such as BioNTech, GSK, the National Institute of Allergy and Infectious Diseases (NIAID), and Vac4All SAS,” Kurdach said.

“No new malaria vaccines are in Phase III development or pre-registration at this time,” she added.